Haemonetics (NYSE:HAE) Price Target Raised to $86.00

Haemonetics (NYSE:HAE) had its target price raised by equities researchers at JPMorgan Chase & Co. from $62.00 to $86.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 0.17% from the stock’s previous close.

Several other research analysts also recently commented on HAE. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. Citigroup reaffirmed a “buy” rating on shares of Haemonetics in a research note on Wednesday, July 29th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. Finally, BTIG Research raised their price target on shares of Haemonetics from $84.00 to $96.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $88.44.

Haemonetics Trading Up 1.0%

NYSE:HAE traded up $0.83 during trading hours on Friday, hitting $85.85. 136,513 shares of the company were exchanged, compared to its average volume of 850,258. The stock has a market capitalization of $3.90 billion, a price-to-earnings ratio of 42.44, a price-to-earnings-growth ratio of 1.69 and a beta of 0.52. Haemonetics has a one year low of $47.31 and a one year high of $88.58. The company has a fifty day simple moving average of $76.59 and a 200 day simple moving average of $66.37. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The business had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.10 EPS. Sell-side analysts expect that Haemonetics will post 5.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Kemnay Advisory Services Inc. purchased a new position in Haemonetics in the 4th quarter worth about $26,000. Leonteq Securities AG purchased a new stake in Haemonetics in the fourth quarter worth approximately $30,000. EverSource Wealth Advisors LLC boosted its position in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Haemonetics in the fourth quarter worth approximately $34,000. Finally, Kelleher Financial Advisors bought a new position in Haemonetics in the second quarter worth approximately $38,000. 99.67% of the stock is owned by institutional investors.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, above the $1.07–$1.08 analyst consensus and up from $1.10 a year earlier. Revenue reached $339.38 million, surpassing the $327.86 million consensus and increasing 5.5% year over year. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook. The company now forecasts reported revenue growth of approximately 5% to 8% for fiscal 2027, with full-year revenue guidance of roughly $1.4 billion. The improved outlook reflects the strong first-quarter performance and provides support for the stock’s earnings-growth narrative. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its price target. BTIG increased its target for Haemonetics from $84 to $96 and reiterated a “Buy” rating, signaling additional potential upside based on the company’s results and outlook. BTIG Raises Haemonetics Price Target
• Negative Sentiment: Initial market reaction was cautious. Despite the earnings beat, reports indicated that the stock declined in premarket trading, suggesting investors may have expected an even stronger outlook or may be taking profits after the recent advance. Haemonetics also trades at a relatively high forward valuation, which can increase sensitivity to guidance and execution.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.